We have shown that interleukin-12 (IL-12) generated a strong, albeit transient, anti-tumor response, mostly mediated by natural killer (NK) cell. T cell participation, in addition to NK cells, was essential for persistence of the antitumor response. Ligation of 4-1BB, a co-stimulatory receptor expressed on activated T cells, is known to amplify T cellmediated immunity. In this study, we compared the effect of a systemically delivered agonistic anti-4-1BB monoclonal antibody (anti-4-1BB mAb) with intra-tumoral adenoviralmediated gene transfer of the 4-1BB ligand (ADV/4-1BBL) to liver metastases in a syngeneic animal model of breast cancer. Both treatments induced a dramatic regression of
Introduction
Every year in the Unites States, over 150 000 new breast cancers are diagnosed and approximately 40 000 women die from this disease. 1 Overall, one in eight women develop breast cancer during her lifetime. Despite an aggressive, combined therapeutic approach, as many as 25% of patients with stage I and II breast cancer, 2 and 50% with stage III, develop metastases within 10 years of diagnosis. 3 For stage IV disease (presence of distant metastases), only palliative or symptomatic treatments can be proposed with a grim prognosis. 4 We, and others, have previously shown prolonged long-term survival rates of animals bearing liver metastases from breast or colon carcinoma treated with interleukin-12 (IL-12) gene therapy 5, 6 or recombinant protein. 7, 8 4-1BB is a co-stimulatory molecule of the tumor necrosis factor (TNF) receptor superfamily expressed at the surface of activated CD4 + or CD8 + T cells. 10, 11 Interaction with its natural 4-1BB ligand (4-1BBL) or agonistic anti-4-1BB antibodies (anti-4-1BB mAb) leads to amplification of T cell-mediated immunity. 12, 13 Systemic administration of agonistic anti-4-1BB mAb could eradicate established subcutaneous (s.c.) tumors in mice through activation of both CD4
+ and CD8 + T cells. 14 In this study, the anti-tumor response induced by triggering of the 4-1BB receptor through systemic administration of anti-4-1BB mAb versus local intra-tumoral delivery of the 4-1BBL gene was compared, both in combination with IL-12 gene therapy. Systemically delivered 4-1BB mAb and local 4-1BBL gene delivery have generated a similar potent anti-tumor immune response, however, through stimulation of a different effector T cell population.
Results

Tumor response study of BALB/c mice bearing established liver metastases from breast carcinoma (n = 10/group) (Figure 1)
We first compared the anti-tumor effect of ADV/4-1BBL injected in pre-established JC liver tumors with anti-4-1BB mAb injected systemically. Animals treated with ADV/4-1BBL virus received control rat Ig, whereas antibody-treated mice received intra-tumoral control ADV/DL312. Animals in a control group were treated with ADV/DL312 and rat Ig. Sizes of liver tumors were compared 14 days after treatment delivery. The mean tumor volume (standard error) was 46.3 (12.7) mm 3 in the ADV/4-1BBL-treated group, 15.8 (10.1) mm 3 in the anti-4-1BB mAb-treated group, and 307.1 (102.9) mm 3 in the ADV/DL312-treated group (P = 0.075, NS was nonsignificant when ADV/4-1BBL was compared with the anti-4-1BB mAb groups; P = 0.009 when the ADV/4-1BBL group was compared with the control group; and P = 0.005 when the anti-4-1BB group was compared with the control group, Wilcoxon rank sum test).
Long-term survival study of BALB/c mice bearing JC breast carcinoma liver metastases treated with ADV/IL-12 + ADV/4-1BB ligand (Figure 2a)
The anti-tumor potential of the combination treatment, ADV/IL-12 and ADV/4-1BBL, was then tested in a longterm survival study of mice bearing pre-established JC liver metastases. Four groups were compared: (1) ADV/IL-12 + ADV/4-1BBL (n = 9); (2) ADV/IL-12 + ADV/DL312 (n = 9); (3) ADV/4-1BBL + ADV/DL312 (n = 8); and (4) ADV/DL312 (n = 8). Seventy-eight percent and 22% of animals in the ADV/IL-12 + ADV/4-1BBL and ADV/IL-12 + ADV/DL312 groups, respectively, showed long-term survival rates (P = 0.035, log rank test). All animals treated with ADV/4-1BBL or ADV/DL312 alone died within 80 to 90 days (P Ͻ 0.001 compared with the ADV/IL-12 + ADV/4-1BBL group, log rank test).
Long-term survival study of BALB/c mice bearing JC breast carcinoma liver metastases treated with intratumoral ADV/IL-12 + systemic anti-4-1BB mAb (Figure 2b)
The anti-tumor effect of the combination ADV/IL-12 and anti-4-1BB mAb was tested in four groups: (1) ADV/IL-12 + anti-4-1BB mAb (n = 23); (2) ADV/DL312 + anti-4- 1BB mAb (n = 25); (3) ADV/IL-12 + rat Ig (n = 12); and (4) ADV/DL312 + rat Ig (n = 14). Eighty-seven percent of mice treated with IL-12 + anti-4-1BB showed long-term survival rates compared with 60% of the ADV/DL312 + anti-4-1BB mAb-treated animals. After treatment with ADV/IL-12+ rat Ig, 42% of the mice were long-term survivors. The difference in survival rates between ADV/IL-12 + anti-4-1BB mAb and ADV/IL-12 + rat Ig-treated animals was statistically significant (P = 0.001, log rank test). All mice in the control group died within 60 to 70 days after tumor-cell inoculation (P Ͻ 0.0001 compared with all groups, log rank test). tumor growth in 100% (6/6) and 20% (1/5) of animals that survived after treatment with ADV/IL-12 + ADV/4-1BBL and ADV/IL-12 + anti-4-1BB mAb, respectively. However, tumor formation was observed in 60% (6/10) and 100% (10/10) of CD8 + T cell-depleted animals after ADV/IL-12 + ADV/4-1BBL and ADV/IL-12 + anti-4-1BB mAb, respectively ( Figure 3 ). It appears that the antitumor response generated after treatment with ADV/IL-12 + 4-1BBL is mediated predominantly by CD4 + T cells (P Ͻ 0.009 for rat Ig-control versus CD4-depleted animals). CD8
Identification of effector T cells involved in the anti
+ T cells ar critical in the antitumor effect in tumor-bearing animals after treatment with ADV/IL-12 + anti-4-1BB mAb (P Ͻ 0.023 for rat Ig-control versus CD8-depleted animals).
Immunostaining of CD4
+ and CD8 + T cells in JC liver tumors after combination-treated animals ( 
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Fisher's exact test). However, no statistically significant difference was noted in comparison to the percentage of animals that rejected the JC cells in the ADV/IL-12 + anti-4-1BB mAb-treated group and control group (P = 0.2, Fisher's exact test).
Interestingly, the rate of tumor growth was reduced dramatically in animals that survived long term for both combination-treatment groups compared with naive animals (Figure 5b) The syngeneic MCA 26 control tumors injected on the opposite flank grew in all (8/8) naive animals, and those that survived long-term after ADV/IL-12 + anti-4-1BB mAb (7/8) and ADV/IL-12 + ADV/4-1BBL (6/7), respectively.
Discussion
We reported previously that intra-tumoral adenoviralmediated IL-12 gene delivery could induce a potent, mostly NK-mediated anti-tumor immune response in a syngeneic animal model of liver metastases of breast cancer. 6 However, this response was short-lasting, allowing for tumor progression and, eventually, death in most of the animals. 6 In addition to NK cells, we have shown that T cell participation was mandatory to achieve persistent anti-tumor immunity, and survival of a majority of tumor-bearing animals. 9 In this study, the ability of a treatment that combined triggering of the 4-1BB costimulatory molecule, either with systemic delivery of agonistic anti-4-1BB mAb or intra-tumoral delivery of ADV/4-1BBL, and intratumoral IL-12 gene therapy was tested to induce regression of pre-established breast liver metastases and persistent anti-tumor immunity. Systemic anti-4-1BB mAb alone induced a dramatic tumor regression compared with intra-tumoral delivery of ADV/4-1BBL and adequate controls. In addition, ADV/4-1BBL alone elicited an anti-tumor response that led to significant tumor volume reduction compared with control ADV/DL312 (P = 0.009). Furthermore, a majority of tumor-bearing animals treated with the combination ADV/IL-12 + anti-4-1BB mAb or ADV/4-1BBL showed long-term survival rates; these animals also had long-lasting tumor-specific immunity. This induced long-term, anti-tumor immune response was even more potent in animals treated initially with intra-tumoral ADV/IL-12 plus ADV/4-1BBL compared with ADV/IL-12 plus anti-4-1BB mAb.
In a previous study, we have shown that infection of JC breast tumor cells with ADV/4-1BBL led to 4-1BBL transgene expression at the cell surface. 15 Moreover, the vast majority of intratumorally injected adenovirus is expressed locally, allowing for restriction of transgene expression at the tumor site with minimal systemic leakage. 16 Intuitively we would have expected systemic delivery of anti-4-1BB mAb to be more effective than local intratumoral implantation of ADV/4-1BBL. According to the physiology and geography of T cell activation, tumor antigens are captured at the tumor site by antigen-presenting cells (APCs). After processing, tumor antigens are expressed at the surface of APCs in the form of MHC class I-or II-peptide complex. APCs migrate to secondary lymphoid organs in which tumor antigen is recognized specifically by naive T cells. T cell-receptor engagement delivers the first activation signal that induces cell-surface expression of co-stimulatory molecules such as 4-1BB. Ligation of the co-stimulatory molecule delivers the second activation signal that leads to full activation of T cells. Most T cells are activated in secondary lymphoid organs. In our experiment, systemic delivery of anti-4-1BB mAb compared with intratumoral administration of ADV/4-1BBL may have led to the ligation of a higher number of 4-1BB-expressing T cells and, thus, optimizing T cell activation. However, intratumoral delivery of ADV/4-1BBL mostly transduces tumor cells known to be poor APCs, and interact with tumor-infiltrating lymphocytes (TILs). In addition, 4-1BBL expression is restricted to the tumor site, thereby reducing the probability for tumor cells to prime naive T cells.
Theoretically, the combination ADV/IL-12 + anti-4-1BB mAb should have induced a stronger anti-tumor immune response than ADV/IL-12 + ADV/4-1BBL. There is no statistically significant difference in the initial tumor response comparing both treatment combinations. However, better tumor protection was observed in long-term survivors after initial treatment with ADV/IL-12 + ADV/4-1BBL (statistically significant compared with ADV/IL-12 + anti-4-1BB mAb). Perhaps tumor-specific T cells were amplified at the tumor site in the instance of locally delivered ADV/4-1BBL. The reason intratumoral delivery of ADV/4-1BB ligand mainly stimulates CD4 + T cells requires further study. CD8
+ T cells have a predominant role in both combination treatment-induced antitumor immune response, as shown in the challenge experiment with depletion of CD8 + T cells. However, the role of CD4 + T cells in this response appeared to be different according to the treatment modality. CD4 + T cell depletion completely abolished the anti-tumor immune response in animals after treatment with ADV/IL-12 + ADV/4-1BBL and led to tumor formation in all animals. On the contrary, CD4
+ T cell depletion after ADV/IL-12 + anti-4-1BB mAb treatment increased the percentage of animals that rejected the tumor challenge compared with control animals (50% versus 20%). CD4 + T cells appear to have a critical, although opposite, role in anti-tumor immune response after both combination treatments. CD4 + T cells may have an essential role in protective immunity either through production of Th1-type cytokine or through direct perforin-dependent or Fas liganddependent cytotoxic mechanisms. Surprisingly, CD4
+ T cells were noted to partially inhibit the anti-tumor response after treatment that combined ADV/IL-12 + anti-4-1BB mAb. This inhibitory effect may be related partially to a shift from a specific T cell subtype activation and cytokine secretion. 17, 18 Triggering of the 4-1BB receptor on T cells through systemic delivery of anti-4-1BB mAb could be responsible for the two opposite functions of CD4 + T cells observed in this study. Adenoviral-mediated intratumoral delivery of the IL-12 and 4-1BBL genes versus IL-12 gene therapy and systemic anti-4-1BB mAb was noted to induce comparable anti-tumor immune response in a syngeneic mouse model of metastatic breast cancer. These results demonstrate that the expression of a co-stimulatory molecule at the tumor site does not diminish its therapeutic potential, but rather induces a more potent long-term, tumor-specific immunity mediated by T cells. This concept might lead to new clinical gene therapy approaches for metastatic breast cancers.
Material and methods
Cell cultures JC (breast) (American Type Culture Collection (ATCC), Manassas, VA, USA) and MCA26 (colon) 19 cells are two chemically induced carcinoma cell lines, derived from a BALB/c background. JC were grown and maintained in minimal essential medium (MEM) (Sigma, St Louis, MO, USA), and MCA26 in high glucose MEM/Ham's Medium F-12 (HAMF12) (Sigma), supplemented with 10% fetal calf serum (Sigma), 2 mM L-glutamine (Sigma), 100 unit/ml penicillin (Sigma), and 100 mg/ml streptomycin (Sigma).
Recombinant adenoviral vectors
Construction of E1-deleted adenoviral vector bearing the murine IL-12 (ADV/IL-12) under the transcriptional control of the Rous sarcoma virus long terminal repeat (RSV-LTR) promoter has been reported previously. 5 The fulllength mouse 4-1BBL complementary deoxyribonucleic acid (cDNA) was obtained from pLXSHDm4- 
In vivo T cell depletion studies
To determine which effector T cell subpopulation is involved in the anti-tumor immune response, in vivo depletion studies using antibodies against CD4 + and CD8 + were performed. Ten days after implantation, intrahepatic JC tumors were treated with either ADV/IL-12 + ADV/4-1BBL or ADV/IL-12 + anti 4-1BB mAb. Seven days later (3 days before virus injection), in vivo CD4 + (purified ascites GK1.5 (ATCC)) or CD8 + T cell (purified ascites 2,43 (ATCC) depletion was performed using specific antibodies, as described previously. 9 Rat Ig was used in control animals after either treatment. Animals received a s.c. challenge of 1 × 10 5 JC parental cells on the flank at day 10 after the virus treatment. The tumor formation was determined at 3 weeks after the challenge.
Immunostaining of JC liver tumors after combination treatment
Immunostaining of CD4
+ and CD8 + T cells in combination-treated animals was performed as described. 22 The animals were killed 7 days after treatment of their JC liver tumor with either ADV/IL-12 + anti 4-1BB mAb or ADV/IL-12 + ADV/4-1BBL. Control animals were treated with ADV/DL312 +/-rat Ig. Tissue through the midsection of the tumors were fixed in tissue-Tek OCT compound (Miles, Elkhart, IN, USA), and stained for immune cell infiltration. Specific cell type CD8 + (53-5.8, PharMingen, San Diego, CA, USA) and CD4 + antibodies (GK 1.5, PharMingen), and anti-FITC secondary antibody conjugated with alkaline phosphatase were used. The staining procedure was then performed according to standard protocol.
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Statistical analysis
To compare the different groups in tumor-response experiments, the Wilcoxon rank sum test was used. The Kaplan-Meier method was used to estimate survival curve in long-term survival studies. Comparisons between survival curves were made by the log-rank test. Each long-term survival study included four groups, with six comparisons being made between groups. To ensure an overall type I error rate of 0.05, each comparison was declared significantly difficult if the P value was less than 0.05/6 = 0.008. To analyze results of the kinetic study of s.c. tumor growth after challenge with parental or unrelated tumor cells and depletion of T cell growth of mice that survived long-term, the following method was applied. For each animal, the average total tumor volume (ATTV) was calculated from days 11 to 22. The ATTV equals the area under the curve (AUC) of the tumor volumes over time divided by the number of days (ATTV = AUC/number of days = AUC/21 -6 = AUC/15). The ATTV represents the average height of the volume-time curve from days 11 to 22, thereby providing an overall index of tumor size. 23 Comparison of ATTVs between groups was performed by the Dunn multiple comparisons procedure for the Kruskal-Wallis test (P = 0.05/number of comparisons). Comparisons between groups of the proportion of animals that developed a tumor were made by Fisher's exact test.
